Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterations
Zanubrutinib shows differential efficacy in Waldenström macroglobulinemia patients depending on the presence of CXCR4 and TP53 mutations, with superior activity in CXCR4-mutated patients and a trend toward better progression‑free survival in TP53-mutated patients.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice
- Milestones in Chronic Lymphocytic Leukemia
- Trial Results Show Majority of Patients With CLL Achieve uMRD With VenO
- On the architecture of translational research designed to control chronic lymphocytic leukemia
- Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)